Adoption of emicizumab (Hemlibra®) for hemophilia A in Europe: Data from the 2020 European Association for Haemophilia and Allied Disorders survey-Reference-Cited by-同舟云学术

Adoption of emicizumab (Hemlibra®) for hemophilia A in Europe: Data from the 2020 European Association for Haemophilia and Allied Disorders survey

Published:2021-06-30 Issue:5 Volume:27 Page:736-743
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Krumb Evelien¹^ORCID,Fijnvandraat Karin²,Makris Michael³^ORCID,Peyvandi Flora⁴⁵^ORCID,Ryan Aislin⁶,Athanasopoulos Angelos⁶,Hermans Cedric¹^ORCID

Affiliation:

1. Hemostasis and Thrombosis Unit Division of Hematology Cliniques universitaires Saint‐Luc Université Catholique de Louvain (UCLouvain) Brussels Belgium

2. Pediatric Hematology Emma Children's Hospital Amsterdam UMC University of Amsterdam Amsterdam Netherlands

3. Sheffield Haemophilia and Thrombosis Centre Sheffield UK

4. Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico Angelo Bianchi Bonomi Hemophilia and Thrombosis Center Milan Italy

5. Department of Pathophysiology and Transplantation Università degli Studi di Milano Milan Italy

6. European Association for Haemophilia and Allied Disorders (EAHAD) Brussels Belgium

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14372

Reference21 articles.

1. Emicizumab: Review of the literature and critical appraisal

2. A Study to Evaluate the Safety Efficacy Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors (HAVEN 6). ClinicalTrials.gov.https://clinicaltrials.gov/ct2/show/NCT04158648 Accessed February 28 2021

3. A Study to Evaluate the Efficacy Safety Pharmacokinetics and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors (HAVEN 7). ClinicalTrials.gov.https://clinicaltrials.gov/ct2/show/NCT04431726 Accessed March 21 2021

4. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies

5. Emicizumab Prophylaxis in Hemophilia A with Inhibitors

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Transitioning patients with severe haemophilia A from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: Real‐world clinical experience;Haemophilia;2024-08-13

2. Final Analysis Results from the AGEHA Study: Emicizumab Prophylaxis for Acquired Hemophilia A with or without Immunosuppressive Therapy;Thrombosis and Haemostasis;2024-08-12

3. Transitioning from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: A simulation study for individuals with severe haemophilia A;Haemophilia;2024-04-29

4. Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B;Cochrane Database of Systematic Reviews;2024-02-27

5. Minimum factor VIII levels to prevent joint bleeding in mild hemophilia A;Blood Advances;2023-11-29